David M. Brown

Ophthalmology · 2006–2019

A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Ophthalmology — 47 citations into it; #95 of 222 by trust here, #10 by citations
• Radiology, Nuclear Medicine and Imaging — 30 citations into it

Whom David M. Brown trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. K. Eng
2. P. Kertes

Who trusts David M. Brown overall

1. N. Ferrara
2. A. Adamis
3. Ursula Schmidt-Erfurth
4. D. Boyer

Papers from David M. Brown's perspective

Ordered by how strongly the researchers David M. Brown trusts endorse each paper. Same corpus, a different order for every researcher.

1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (New England Journal of Medicine)
2. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. (American journal of ophthalmology-glaucoma)
3. DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (Retina)
4. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. (Ophthalmology (Rochester, Minn.))
5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
6. Pegaptanib for neovascular age-related macular degeneration. (New England Journal of Medicine)
7. INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION (Retina)
8. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. (Ophthalmology (Rochester, Minn.))
9. Ranibizumab in neovascular age-related macular degeneration (Clinical Interventions in Aging)
10. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Their papers

• HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (2019) — 810 citations
• Intravitreal aflibercept for diabetic macular edema. (2014) — 842 citations
• Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014) — 809 citations
• Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. (2013) — 853 citations
• Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (2012) — 2,368 citations
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. (2010) — 1,107 citations
• Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (2009) — 1,448 citations
• Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. (2008) — 888 citations
• ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) — 690 citations
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (2006) — 3,445 citations
• Ranibizumab for neovascular age-related macular degeneration. (2006) — 2,821 citations